Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors

Trial Profile

Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2009

At a glance

  • Drugs SNS 314 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, according to a Sunesis media release.
    • 15 May 2008 The expected completion date for this trial is now 1 Mar 2009, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top